Physician profile
Michael X Pham
NPI 1194735019
$9,126.06
in general payments reported to CMS, 2019-2025
28 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,791 · 2020: $400 · 2021: $729 · 2022: $2,368 · 2023: $198 · 2024: $661 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479 · Travel and Lodging: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.12 |
| Travel and Lodging | $1,358.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,452.42 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $1,484.90 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $1,366.32 | 2025 | |
| Amgen INC. | $765.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $404.11 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $371.62 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $128.88 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals Lp | $105.84 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $96.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $94.04 | 2019-2020 | |
| Abbvie INC. | $80.97 | 2021-2022 | |
| Heartflow, INC. | $76.49 | 2019-2021 | |
| Irhythm Technologies, INC. | $74.94 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $74.21 | 2019-2025 | Onpattro |
| Pfizer INC. | $70.49 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $62.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.95 | 2020-2024 | Camzyos |
| Teleflex LLC | $59.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.26 | 2019-2022 | |
| Paragonix Technologies, INC. | $43.88 | 2025 | Sherpapak |
| Astellas Pharma US INC | $39.26 | 2020 | |
| Novo Nordisk INC | $32.45 | 2025 | Rybelsus, Ozempic |
| Cvrx, INC. | $31.85 | 2024 | Barostim Neo System |
| One Lambda, INC. | $28.72 | 2024 | |
| Cathworks, INC. | $26.32 | 2020 | |
| Gilead Sciences, INC. | $22.75 | 2019 | |
| Lundbeck LLC | $21.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.